RxDoctor Payments DataLook up a doctor →

Raj Nagaraj, MD

Endocrinology, Diabetes & Metabolism · Noblesville, INNPI 1104935147

Payments from drug & device makers

$7,907in general payments, 2019–2025

Across 441 payments — averaging $17.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$627
  • Novo Nordisk$610
  • Lilly USA, LLC$585
  • AstraZeneca$504
  • Sanofi-aventis U.S. LLC$424
  • Abbott$422
  • plus $5K from 49 others

What the payments were for

  • Food & beverage$7,76198%
  • Education$871%
  • Gifts$591%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,907 in reported general payments places this provider in the 70th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.

See all endocrinology, diabetes & metabolism providers in Indiana

Medicare billing

Part B allowed, 2024
$179,110
Medicare patients
474
Services billed
3,953

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide371$548,961
JardianceEmpagliflozin206$212,153
TrulicityDulaglutide142$183,560
MounjaroTirzepatide130$162,267
JanumetSitagliptin Phos/Metformin Hcl112$117,765
Tresiba Flextouch U-100Insulin Degludec118$93,688
Humalog Kwikpen U-100Insulin Lispro225$75,174
TradjentaLinagliptin92$74,418
ForteoTeriparatide14$60,884
FarxigaDapagliflozin Propanediol68$59,982
Lantus SolostarInsulin Glargine,hum.Rec.Anlog310$55,998
Humulin R U-500 KwikpenInsulin Regular, Human24$55,960
JanuviaSitagliptin Phosphate42$52,236
Fiasp FlextouchInsulin Aspart (Niacinamide)62$48,262
Janumet XrSitagliptin Phos/Metformin Hcl39$39,771

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$610$585,987385 claims
Lilly USA, LLCTrulicity, Mounjaro, Forteo, Humalog, Humulin N$585$423,208359 claims
Boehringer IngelheimJardiance, Tradjenta, Jentadueto$307$292,245309 claims
MerckJanumet, Januvia, Janumet Xr$46$209,772193 claims
AstraZenecaFarxiga$504$59,98268 claims
AmgenProlia$627$33,90119 claims
AbbVieSynthroid$253$15,107157 claims
Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus$424$13,90938 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$224$4,062556 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.

Other endocrinology, diabetes & metabolism in Noblesville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →